Navigation Links
INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research, Co-Invest in Sanguine BioSciences

SANTA MONICA, Calif., March 7, 2013 /PRNewswire/ -- INVENT Ventures, Inc. (OTC QB: IDEA), a seed-stage venture fund and technology incubator, today announced that it has led the seed financing round in Sanguine BioSciences, a biotechnology company empowering patients in biomedical research. Along with INVENT, Heliant Ventures, a VC technology fund, jointly lead the round of investment in Sanguine.

INVENT's investment in Sanguine keeps with its strategy of building and investing in evolving and rapidly growing companies. In addition to Sanguine BioSciences, which supplies DNA data and bio-specimen to research organizations for the development of personalized medicines, INVENT has also developed Virurl Inc., one of the early pioneers in native advertising. Virurl builds tools and technologies to create native advertising campaigns, and has raised $1.2M in seed financing to date. Since formation in 2010, INVENT has built six technology companies, which have raised over $3.5M at an aggregate valuation over $10M, with under $450K of capital investment.

"We are thrilled to invest in Sanguine alongside Heliant Ventures and to further reinforce our holdings in what we believe are the next generation of exciting young technology companies," said Bryce Knight , CEO of INVENT. "With Sanguine, Virurl and our other portfolio companies, we have strong positions in technology businesses that are readily scalable, and we believe that each has the potential to go public if they elect to. Considering the vast value creation ability of technology companies, private and public investors alike are looking for exposure to early-stage technology, and we are very excited to be in a position to fulfill this need."

About INVENT Ventures, Inc.
INVENT Ventures Inc. (IDEA) is a publicly traded venture fund that builds and invests in transformative technology businesses. INVENT pursues ventures in the consumer Internet, mobile and biotechnology markets, and has built six companies at various stages of development. INVENT is headquartered in Santa Monica, California in the renowned Silicon Beach area. For more information on INVENT, visit

Forwarding-Looking Statements
Cautionary Language Regarding Forward Looking Statements: This release and any attachments contain forward-looking statements within the meaning of the "safe harbor" provisions of the Federal securities laws, including Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties. Words such as "will," "believe," "intend," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include the quotations from management in this press release, as well as any statements regarding the Company's anticipated financial results and strategic and operational plans. The Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may contribute to such differences include, but are not limited to: the Company's ability to deliver an adequate rate of growth and manage such growth; the impact of changes in government regulation and industry standards; the Company's ability to maintain and increase the number of visitors to its websites; the Company's ability to identify and manage acquisitions; the impact of the current economic climate on the Company's business; the Company's ability to attract and retain qualified executives and employees; the Company's ability to compete effectively against others in the online marketing and media industry; the impact and costs of any failure by the Company to comply with government regulations and industry standards; and costs associated with defending intellectual property infringement and other claims. More information about potential factors that could affect the Company's business and financial results is contained in the Company's latest annual report. These forward looking statements are made as of today's date and, except as otherwise required by law, the Company does not intend and undertakes no duty to release publicly any updates or revisions to any forward-looking statements contained herein to reflect events or circumstances after the date hereof.

SOURCE INVENT Ventures, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
2. Researchers invent acoustic-assisted magnetic information storage
3. Cellphone Microscope Inventor Honored with Biophotonics Technology Innovator Award
4. Cieri Media Announces New Science Series 'Bright Ideas' Focusing on Latest Inventions
5. NTUs sense-ational invention helps underwater vessels navigate with ease
6. Collegiate Inventors Honored for Innovative Science and Technology Advances
7. Gevo Doesnt Infringe Butamaxs 017 Patent; Gevo was First to Invent Enzyme in 017 Patent; Gevo has Advanced Beyond That and Now Uses Different Enzymes
8. PharmaVOICE Names Four inVentiv Health Associates Among "100 Most Inspiring" Leaders in Healthcare
9. University of Utah physicists invent spintronic LED
10. RURO Adds Critical Level Monitoring Functionality to its Inventory Management Software FreezerPro.
11. Ocean Tomo Study Ranks Top 25 Most Inventive Illinois Companies in 2011 for Crain’s Chicago Business
Post Your Comments:
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader SAP ... states to develop and pitch their BIG ideas to improve health and wellness in ... for votes to win the title of SAP's Teen Innovator, an all-expenses paid trip ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... -- Connected health pioneer, Joseph C. Kvedar , MD, ... and wellness, and the business opportunities that arise from ... of Healthy Things . Long before health and ... Kvedar, vice president, Connected Health, Partners HealthCare, was creating ... from the hospital or doctor,s office into the day-to-day ...
(Date:10/27/2015)... 27, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... Google has adopted the Synaptics ® ClearPad ® ... power its newest flagship smartphones, the Nexus 5X by ... --> --> Synaptics works ... strategic collaboration in the joint development of next generation ...
Breaking Biology News(10 mins):